AbbVie Inc (ABBV) surpasses earnings expectations with robust growth in immunology and neuroscience, despite facing significant Humira sales decline.

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

(Reuters) - The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to ...

Biocon Biologics, a unit of Biocon (BION.NS), opens new tab, said Hulio would be available at a list price of 5% below Humira's current list price. Humira comes at list price of $6,922 per carton. The ...

Amgen Inc. is challenging one of the world’s best-selling medications with an unusual strategy: charging two list prices for the same medicine. The company on Tuesday launched Amjevita, the first ...

This was expected to be the year that Humira, AbbVie ‘s blockbuster $90,000-a-year arthritis treatment and the best-selling biopharmaceutical in history, loses its chokehold on the healthcare system.

AbbVie's earnings topped estimates, and it offered an upbeat view of 2025 AbbVie Inc.'s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and ...

July 3 (Reuters) - The generic drug unit of Germany's Fresenius (FREG.DE), opens new tab said on Monday the price for Idacio, its copycat version of Abbvie's (ABBV.N), opens new tab top-selling ...